The Jewish General Hospital Cell Processing Center

The JGH CPC is designed as an enabling infrastructure to support the prosecution of early phase clinical trials of cell-based therapies where processing of human cell and tissue is required as part of the study.  The objective of this facility is to render accessible to the patient community cutting edge, experimental cellular pharmaceuticals for treatment of human catastrophic illnesses.  It promotes development of technologies from institutional scientists as well as partnership development of technologies from other biomedical institutions, academic networks, biotechnology firms and pharmaceutical industry.  The JGH CPC’s successful development is optimized within an environment of cooperation on a regional and national scale.  The JGH CPC is part of the McGill family of enabling infrastructures and has established links with many Quebec-based Medical Schools. It is currently supported in part by a National Center of Excellence, the “Canadian Stem Cell Network (SCN)”, and is also developed as a biotech and pharmaceutical service contract facility through sponsorship by “Northern Therapeutics Inc.” of an ongoing cell and gene therapy clinical trial in primary pulmonary hypertension, the first cell and gene therapy trial in Canada.
Support research at the Lady Davis Institute - Jewish General Hospital